June 1, 2023
USPTO Grants Notice of Allowance for Tenax Therapeutics’ Oral Levosimendan
The HELP Study’s findings are the foundation for the oral levosimendan patent. Tenax Therapeutics’ patent application for its oral levosimendan, TNX-103, to treat pulmonary hypertension combined with ...
The HELP Study’s findings are the foundation for the oral levosimendan ...